首页 > 最新文献

Cancer diagnosis & prognosis最新文献

英文 中文
Pleomorphic Rhabdomyosarcoma of the Uterine Corpus in an Adult Who Underwent Multi-gene Panel Testing. 接受多基因组检测的成人子宫体多形性横纹肌肉瘤
Pub Date : 2024-05-03 eCollection Date: 2024-05-01 DOI: 10.21873/cdp.10333
Tamami Odai, Noriko Oshima, Yusuke Kori, Maki Takao, Kimio Wakana, Naoyuki Miyasaka

Background/aim: Rhabdomyosarcoma (RMS) is the most common malignant soft tissue tumor in children. Adult primary RMS of gynecological origin is a rare condition and uterine RMS is an aggressive malignancy with a poor prognosis. The genetic variants associated with uterine RMS in adults have yet to be fully elucidated, and there is no established therapeutic strategy for rare tumors.

Case report: A 69-year-old Japanese woman was referred to our hospital with abdominal bloating. Imaging examination revealed a tumor with diameter of 85 mm located in the uterus and multiple regional lymph node metastases. Biopsy of the uterine corpus indicated possible uterine carcinosarcoma or RMS. Following debulking surgery, the patient was diagnosed with stage IVB pleomorphic RMS. The patient was treated with two courses of doxorubicin every three weeks and one course of combination chemotherapy with vincristine, actinomycin, and cyclophosphamide. Because of rapid progression of the disease, we decided to perform multi-gene panel testing to determine the most effective therapeutic strategy. However, no therapeutic plan based on genetic information was identified. The patient with chemotherapy-refractory RMS died 11 weeks after surgery.

Conclusion: Our patient had advanced uterine RMS with an unresectable tumor that was resistant to chemotherapy, resulting in poor outcomes. Despite conducting multi-gene panel testing, no tailored therapeutic approach based on genetic information was found. This case highlights the challenges in managing uterine RMS in adults and underscores the urgent need for further research to identify effective treatment modalities.

背景/目的:横纹肌肉瘤(RMS)是儿童最常见的恶性软组织肿瘤。成人妇科原发性横纹肌肉瘤较为罕见,而子宫横纹肌肉瘤是一种侵袭性恶性肿瘤,预后较差。与成人子宫RMS相关的基因变异尚未完全阐明,目前也没有针对罕见肿瘤的成熟治疗策略:病例报告:一名 69 岁的日本妇女因腹胀转诊至我院。影像学检查显示,肿瘤位于子宫内,直径 85 毫米,并有多个区域淋巴结转移。子宫体活检显示可能是子宫癌肉瘤或RMS。切除手术后,患者被诊断为多形性 RMS IVB 期。患者接受了两个疗程的多柔比星治疗(每三周一次)和一个疗程的长春新碱、放线菌素和环磷酰胺联合化疗。由于病情进展迅速,我们决定进行多基因面板检测,以确定最有效的治疗策略。然而,我们并没有找到基于基因信息的治疗方案。化疗难治性RMS患者在术后11周死亡:结论:我们的患者患有晚期子宫RMS,肿瘤无法切除,对化疗产生耐药性,导致治疗效果不佳。尽管进行了多基因面板检测,但仍未找到基于基因信息的定制治疗方法。该病例凸显了治疗成人子宫RMS所面临的挑战,并强调急需进一步研究以确定有效的治疗方法。
{"title":"Pleomorphic Rhabdomyosarcoma of the Uterine Corpus in an Adult Who Underwent Multi-gene Panel Testing.","authors":"Tamami Odai, Noriko Oshima, Yusuke Kori, Maki Takao, Kimio Wakana, Naoyuki Miyasaka","doi":"10.21873/cdp.10333","DOIUrl":"https://doi.org/10.21873/cdp.10333","url":null,"abstract":"<p><strong>Background/aim: </strong>Rhabdomyosarcoma (RMS) is the most common malignant soft tissue tumor in children. Adult primary RMS of gynecological origin is a rare condition and uterine RMS is an aggressive malignancy with a poor prognosis. The genetic variants associated with uterine RMS in adults have yet to be fully elucidated, and there is no established therapeutic strategy for rare tumors.</p><p><strong>Case report: </strong>A 69-year-old Japanese woman was referred to our hospital with abdominal bloating. Imaging examination revealed a tumor with diameter of 85 mm located in the uterus and multiple regional lymph node metastases. Biopsy of the uterine corpus indicated possible uterine carcinosarcoma or RMS. Following debulking surgery, the patient was diagnosed with stage IVB pleomorphic RMS. The patient was treated with two courses of doxorubicin every three weeks and one course of combination chemotherapy with vincristine, actinomycin, and cyclophosphamide. Because of rapid progression of the disease, we decided to perform multi-gene panel testing to determine the most effective therapeutic strategy. However, no therapeutic plan based on genetic information was identified. The patient with chemotherapy-refractory RMS died 11 weeks after surgery.</p><p><strong>Conclusion: </strong>Our patient had advanced uterine RMS with an unresectable tumor that was resistant to chemotherapy, resulting in poor outcomes. Despite conducting multi-gene panel testing, no tailored therapeutic approach based on genetic information was found. This case highlights the challenges in managing uterine RMS in adults and underscores the urgent need for further research to identify effective treatment modalities.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140873663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating the Difference in Quality of Life Between Immediate and Delayed Breast Cancer Reconstruction: A Systematic Review. 调查乳腺癌即时重建与延迟重建在生活质量上的差异:系统回顾。
Pub Date : 2024-05-03 eCollection Date: 2024-05-01 DOI: 10.21873/cdp.10312
Vlasios Tsantakis, Dimitrios A Dimitroulis, Konstantinos C Kontzoglou, Nikolaos I Nikiteas

Background/aim: Immediate and delayed breast reconstruction remains a controversial topic. Apart from the clinical outcomes that have to be considered, there is a discrepancy of opinions regarding the potential differences in quality of life. It is essential to clarify this issue, in order to contribute to the reconstruction of the decision-making process. The aim of the study was to investigate potential differences in quality of life between immediate and delayed breast reconstruction patients.

Materials and methods: A systematic review of the literature was carried out, searching for case-control studies that have comparatively examined the effects of delayed and immediate reconstruction on quality of life. A literature search was carried out using the Medline, Scopus and Web of Science databases. The quality of the studies was evaluated using the STROBE checklist for case-control studies.

Results: Three studies were found showing that immediate reconstruction led to benefits for the quality of life of patients, while one study showed the opposite. A relevant study revealed no statistically significant differences between the two groups, while another study, showed that immediate reconstruction entailed short-term benefits to quality of life. Four of the studies had debatable methodological approaches.

Conclusion: The inconsistent study findings cannot lead to any reliable conclusions regarding differences between immediate and delayed reconstruction in quality of life. It is possible that the results vary due to the time point that the comparisons made. Future research to this direction is warranted.

背景/目的:立即和延迟乳房再造仍然是一个有争议的话题。除了必须考虑的临床结果外,在生活质量的潜在差异方面也存在意见分歧。有必要澄清这一问题,以便为重建决策过程做出贡献。本研究旨在调查即刻和延迟乳房重建患者在生活质量方面的潜在差异:我们对文献进行了系统性回顾,搜索了对延迟重建和立即重建对生活质量的影响进行比较研究的病例对照研究。我们使用 Medline、Scopus 和 Web of Science 数据库进行了文献检索。研究质量采用 STROBE 病例对照研究核对表进行评估:结果:发现有三项研究表明,立即重建可提高患者的生活质量,而一项研究则相反。一项相关研究显示,两组患者在统计学上没有显著差异,而另一项研究则显示,即刻重建可在短期内提高生活质量。其中四项研究的方法值得商榷:结论:研究结果不一致,无法就立即重建和延迟重建在生活质量方面的差异得出任何可靠的结论。可能由于比较的时间点不同,结果也不尽相同。未来有必要对此进行研究。
{"title":"Investigating the Difference in Quality of Life Between Immediate and Delayed Breast Cancer Reconstruction: A Systematic Review.","authors":"Vlasios Tsantakis, Dimitrios A Dimitroulis, Konstantinos C Kontzoglou, Nikolaos I Nikiteas","doi":"10.21873/cdp.10312","DOIUrl":"https://doi.org/10.21873/cdp.10312","url":null,"abstract":"<p><strong>Background/aim: </strong>Immediate and delayed breast reconstruction remains a controversial topic. Apart from the clinical outcomes that have to be considered, there is a discrepancy of opinions regarding the potential differences in quality of life. It is essential to clarify this issue, in order to contribute to the reconstruction of the decision-making process. The aim of the study was to investigate potential differences in quality of life between immediate and delayed breast reconstruction patients.</p><p><strong>Materials and methods: </strong>A systematic review of the literature was carried out, searching for case-control studies that have comparatively examined the effects of delayed and immediate reconstruction on quality of life. A literature search was carried out using the Medline, Scopus and Web of Science databases. The quality of the studies was evaluated using the STROBE checklist for case-control studies.</p><p><strong>Results: </strong>Three studies were found showing that immediate reconstruction led to benefits for the quality of life of patients, while one study showed the opposite. A relevant study revealed no statistically significant differences between the two groups, while another study, showed that immediate reconstruction entailed short-term benefits to quality of life. Four of the studies had debatable methodological approaches.</p><p><strong>Conclusion: </strong>The inconsistent study findings cannot lead to any reliable conclusions regarding differences between immediate and delayed reconstruction in quality of life. It is possible that the results vary due to the time point that the comparisons made. Future research to this direction is warranted.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140859195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Speedy/RINGO Protein in Breast Cancer as a Future Biomarker. 乳腺癌中的 Speedy/RINGO 蛋白作为未来生物标志物的作用。
Pub Date : 2024-05-03 eCollection Date: 2024-05-01 DOI: 10.21873/cdp.10310
Ozgur Tanriverdi, Aysegul Yildiz

Background/aim: Cyclin-dependent kinases (CDKs) are proteins that require the binding of regulatory subunits called cyclins and play a key role in cell cycle progression and activation. CDKs play a key role in carcinogenesis of many solid malignancies, and inhibition of these proteins has produced anti-cancer effects demonstrated in preclinical studies. This narrative review was conducted to develop a hypothetical approach to determine whether Speedy/RINGO, a protein associated with CDK2, could be a possible predictive factor in breast cancer patients treated with a CDK4/6 inhibitor.

Materials and methods: A literature search was conducted in PubMed, Web of Science, Medline, and Google Scholars search engines to match the following words: "Speedy/RINGO" or "Spy1" and "CDKs" or "Cyclin-dependent kinases (CDKs)" and "CDK4/6 inhibitors" and "Regulation" and "Molecular" and "Breast cancer" and "Carcinogenesis". Only articles investigating the relationship between the Speedy/RINGO protein and CDKs at the molecular level were included. Literature information was compiled by trying to establish a relationship with our hypothesis question.

Results: Speedy/RINGO is a tightly regulated proto-oncogenic mammalian protein playing important roles in the somatic cell cycle. Studies have emphasized that although it does not have amino acid sequence homology with cyclins, it can activate CDK2. In addition, results showing molecular compensation of CDK4/6 inhibition through CDK2 activation, also showed that CDK2 can predict drug resistance. Another important finding was that overexpressed Speedy/RINGO, during CDK4/6 inhibitor treatment, could strongly activate CDK2, resulting in a negative response to treatment.

Conclusion: Although many predictive factors have been investigated to indicate response to CDK4/6 inhibitors or determine drug resistance, a consensus biomarker has yet to be established. In light of the information obtained from our review, it can be concluded that the Speedy/RINGO protein may have an important role as a predictive biomarker in terms of response to treatment, continuity of treatment and drug resistance in patients treated with CDK4/6 inhibitors.

背景/目的:细胞周期蛋白依赖性激酶(CDKs)是一种需要与称为细胞周期蛋白的调控亚基结合的蛋白质,在细胞周期的进展和活化中起着关键作用。CDK 在许多实体恶性肿瘤的致癌过程中发挥着关键作用,临床前研究表明,抑制这些蛋白可产生抗癌效果。本叙述性综述旨在开发一种假设性方法,以确定与 CDK2 相关的蛋白质 Speedy/RINGO 是否可能成为接受 CDK4/6 抑制剂治疗的乳腺癌患者的预测因素:在 PubMed、Web of Science、Medline 和 Google Scholars 搜索引擎上进行文献检索,以匹配以下词条:"Speedy/RINGO "或 "Spy1 "和 "CDKs "或 "依赖细胞周期蛋白的激酶(CDKs)"和 "CDK4/6 抑制剂 "和 "调节 "和 "分子 "和 "乳腺癌 "和 "致癌"。只有在分子水平上研究 Speedy/RINGO 蛋白和 CDK 之间关系的文章才被收录。通过尝试建立与我们的假设问题之间的关系,对文献信息进行了汇编:Speedy/RINGO是一种受到严格调控的哺乳动物原癌蛋白,在体细胞周期中发挥着重要作用。研究强调,虽然它与细胞周期蛋白没有氨基酸序列同源性,但它能激活 CDK2。此外,通过激活 CDK2 对 CDK4/6 抑制作用进行分子补偿的结果也表明,CDK2 可以预测耐药性。另一个重要发现是,在CDK4/6抑制剂治疗期间,过表达的Speedy/RINGO可强烈激活CDK2,从而导致对治疗的负反应:尽管已经研究了许多预测因素,以显示对 CDK4/6 抑制剂的反应或确定耐药性,但尚未建立一个共识生物标志物。根据我们的综述所获得的信息,可以得出结论:Speedy/RINGO 蛋白作为一种预测性生物标志物,可能对 CDK4/6 抑制剂治疗患者的治疗反应、治疗持续性和耐药性具有重要作用。
{"title":"The Role of Speedy/RINGO Protein in Breast Cancer as a Future Biomarker.","authors":"Ozgur Tanriverdi, Aysegul Yildiz","doi":"10.21873/cdp.10310","DOIUrl":"https://doi.org/10.21873/cdp.10310","url":null,"abstract":"<p><strong>Background/aim: </strong>Cyclin-dependent kinases (CDKs) are proteins that require the binding of regulatory subunits called cyclins and play a key role in cell cycle progression and activation. CDKs play a key role in carcinogenesis of many solid malignancies, and inhibition of these proteins has produced anti-cancer effects demonstrated in preclinical studies. This narrative review was conducted to develop a hypothetical approach to determine whether Speedy/RINGO, a protein associated with CDK2, could be a possible predictive factor in breast cancer patients treated with a CDK4/6 inhibitor.</p><p><strong>Materials and methods: </strong>A literature search was conducted in PubMed, Web of Science, Medline, and Google Scholars search engines to match the following words: \"Speedy/RINGO\" or \"Spy1\" and \"CDKs\" or \"Cyclin-dependent kinases (CDKs)\" and \"CDK4/6 inhibitors\" and \"Regulation\" and \"Molecular\" and \"Breast cancer\" and \"Carcinogenesis\". Only articles investigating the relationship between the Speedy/RINGO protein and CDKs at the molecular level were included. Literature information was compiled by trying to establish a relationship with our hypothesis question.</p><p><strong>Results: </strong>Speedy/RINGO is a tightly regulated proto-oncogenic mammalian protein playing important roles in the somatic cell cycle. Studies have emphasized that although it does not have amino acid sequence homology with cyclins, it can activate CDK2. In addition, results showing molecular compensation of CDK4/6 inhibition through CDK2 activation, also showed that CDK2 can predict drug resistance. Another important finding was that overexpressed Speedy/RINGO, during CDK4/6 inhibitor treatment, could strongly activate CDK2, resulting in a negative response to treatment.</p><p><strong>Conclusion: </strong>Although many predictive factors have been investigated to indicate response to CDK4/6 inhibitors or determine drug resistance, a consensus biomarker has yet to be established. In light of the information obtained from our review, it can be concluded that the Speedy/RINGO protein may have an important role as a predictive biomarker in terms of response to treatment, continuity of treatment and drug resistance in patients treated with CDK4/6 inhibitors.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062167/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Renal Failure Without Hemodialysis Is a Risk Factor for Postoperative Complications in Colorectal Cancer Surgery. 未经血液透析的肾功能衰竭是结直肠癌手术术后并发症的一个风险因素。
Pub Date : 2024-05-03 eCollection Date: 2024-05-01 DOI: 10.21873/cdp.10323
Takaaki Fujimoto, Shigetaka Inoue, Taketo Matsunaga, Toru Shimizu, Haruka Mitsubuchi, Takahito Matsuyoshi, Kaou Matsuda, Soshi Terasaka, Takaharu Yasui, Chizu Kameda, Yasuhiro Ogura, Junji Ueda, Kentaro Nakai, Masanori Tokumoto, Kenichi Nishiyama, Kentaro Motoyama, Eishi Nagai, Yuji Nakafusa

Background/aim: Surgical outcomes of colorectal cancer (CRC) in patients with renal failure (RF) remain to be clarified. The objective of this research was to investigate how RF impacts the surgical outcomes in patients with CRC.

Patients and methods: A retrospective analysis was performed on clinical data from 633 patients who underwent colorectal resection for CRC between January 2017 and December 2021. Outcomes of the patients with and without RF were compared. RF was defined as estimated Glomerular Filtration Rate less than 30.

Results: Forty-five (7%) patients with RF were identified. RF was a significant risk factor for postoperative complications after colorectal cancer surgery (odds ratio=2.19, 95% confidence interval=1.08-4.42, p=0.0284). The patients with RF had significantly more comorbidity (p=0.016), and higher American Society of Anesthesiologists physical status (p<0.01). Hemoglobin level (p<0.01) and PNI (p<0.01) were significantly lower in those with RF. Postoperative complications were significantly higher (p=0.016), and the postoperative hospital stay was significantly longer (p<0.01) among patients with RF compared to those without RF. Patients with RF, excluding those undergoing hemodialysis, had significantly more complications compared to those without RF (p=0.004).

Conclusion: Careful attention should be paid to perioperative management in RF colorectal cancer patients.

背景/目的:肾功能衰竭(RF)患者结直肠癌(CRC)的手术效果仍有待明确。本研究旨在探讨肾功能衰竭如何影响 CRC 患者的手术效果:对2017年1月至2021年12月期间因CRC接受结直肠切除术的633名患者的临床数据进行了回顾性分析。比较了有 RF 和无 RF 患者的预后。RF定义为估计肾小球滤过率小于30.结果:结果:共发现 45 例(7%)RF 患者。RF是结直肠癌术后并发症的重要风险因素(几率比=2.19,95%置信区间=1.08-4.42,P=0.0284)。RF患者的合并症明显较多(p=0.016),美国麻醉医师协会体能状态较高(pConclusion):射频结直肠癌患者的围手术期管理应得到仔细关注。
{"title":"Renal Failure Without Hemodialysis Is a Risk Factor for Postoperative Complications in Colorectal Cancer Surgery.","authors":"Takaaki Fujimoto, Shigetaka Inoue, Taketo Matsunaga, Toru Shimizu, Haruka Mitsubuchi, Takahito Matsuyoshi, Kaou Matsuda, Soshi Terasaka, Takaharu Yasui, Chizu Kameda, Yasuhiro Ogura, Junji Ueda, Kentaro Nakai, Masanori Tokumoto, Kenichi Nishiyama, Kentaro Motoyama, Eishi Nagai, Yuji Nakafusa","doi":"10.21873/cdp.10323","DOIUrl":"https://doi.org/10.21873/cdp.10323","url":null,"abstract":"<p><strong>Background/aim: </strong>Surgical outcomes of colorectal cancer (CRC) in patients with renal failure (RF) remain to be clarified. The objective of this research was to investigate how RF impacts the surgical outcomes in patients with CRC.</p><p><strong>Patients and methods: </strong>A retrospective analysis was performed on clinical data from 633 patients who underwent colorectal resection for CRC between January 2017 and December 2021. Outcomes of the patients with and without RF were compared. RF was defined as estimated Glomerular Filtration Rate less than 30.</p><p><strong>Results: </strong>Forty-five (7%) patients with RF were identified. RF was a significant risk factor for postoperative complications after colorectal cancer surgery (odds ratio=2.19, 95% confidence interval=1.08-4.42, p=0.0284). The patients with RF had significantly more comorbidity (p=0.016), and higher American Society of Anesthesiologists physical status (p<0.01). Hemoglobin level (p<0.01) and PNI (p<0.01) were significantly lower in those with RF. Postoperative complications were significantly higher (p=0.016), and the postoperative hospital stay was significantly longer (p<0.01) among patients with RF compared to those without RF. Patients with RF, excluding those undergoing hemodialysis, had significantly more complications compared to those without RF (p=0.004).</p><p><strong>Conclusion: </strong>Careful attention should be paid to perioperative management in RF colorectal cancer patients.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140863854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postoperative Lymph Node Recurrence in Esophageal Cancer After Surgery and Prognosis of Chemoradiotherapy. 食管癌术后淋巴结复发与化疗放疗的预后
Pub Date : 2024-05-03 eCollection Date: 2024-05-01 DOI: 10.21873/cdp.10320
Manabu Emi, Yoichi Hamai, Toru Yoshikawa, Ryosuke Hirohata, Manato Ohsawa, Tomoaki Kurokawa, Yuji Murakami, Ikuno Nishibuchi, Morihito Okada

Background/aim: This study aimed to evaluate the long-term prognosis of definitive chemoradiotherapy and clinical features of postoperative lymph node (LN) recurrence after curative resection of thoracic esophageal squamous cell cancer (ESCC).

Patients and methods: A total of 586 patients who underwent radical resection of ESCC at the Hiroshima University Hospital from January 2000 to December 2019 were reviewed retrospectively. This study analyzed the clinical characteristics of 54 patients who developed recurrence in a solitary LN by comparing them to 182 patients who experienced total recurrence. Additionally, we analyzed the prognostic factors of 50 patients who received chemo-radiotherapy (CRT).

Results: The results revealed a tendency for a higher incidence of solitary LN recurrence in cases of early esophageal cancer and upper thoracic esophageal cancer among all recurrence cases. The 3-, 5-, and 7-year overall survival (OS) rates were 40.5%, 37.8% and 34.6%, respectively, with a median survival time of 27.9 months. Univariate analysis of OS factors, such as age, depth of the primary tumor at the initial surgery, time to LN recurrence after surgery, site of LN recurrence, and the number of the regional LNs with recurrence showed no significant impact on OS.

Conclusion: Approximately 35% of patients with ESCC who experienced LN recurrence after curative resection achieved long-term survival through CRT. Despite the absence of identifiable prognostic factors, CRT proves to be a valuable initial treatment option for LN recurrence.

背景/目的:本研究旨在评估胸腔食管鳞状细胞癌(ESCC)根治性切除术后明确化放疗的长期预后和术后淋巴结(LN)复发的临床特征:回顾性分析了2000年1月至2019年12月期间在广岛大学医院接受ESCC根治性切除术的586例患者。本研究分析了54例单发LN复发患者与182例完全复发患者的临床特征。此外,我们还分析了50名接受化疗放疗(CRT)患者的预后因素:结果:结果显示,在所有复发病例中,早期食管癌和上胸段食管癌单发LN复发率较高。3年、5年和7年总生存率(OS)分别为40.5%、37.8%和34.6%,中位生存时间为27.9个月。对年龄、初次手术时原发肿瘤深度、术后LN复发时间、LN复发部位和复发区域LN数量等OS因素进行的单变量分析表明,这些因素对OS无显著影响:结论:约有35%的ESCC患者在根治性切除术后出现LN复发,通过CRT获得了长期生存。尽管缺乏可识别的预后因素,但事实证明 CRT 是治疗 LN 复发的一种有价值的初始治疗方案。
{"title":"Postoperative Lymph Node Recurrence in Esophageal Cancer After Surgery and Prognosis of Chemoradiotherapy.","authors":"Manabu Emi, Yoichi Hamai, Toru Yoshikawa, Ryosuke Hirohata, Manato Ohsawa, Tomoaki Kurokawa, Yuji Murakami, Ikuno Nishibuchi, Morihito Okada","doi":"10.21873/cdp.10320","DOIUrl":"https://doi.org/10.21873/cdp.10320","url":null,"abstract":"<p><strong>Background/aim: </strong>This study aimed to evaluate the long-term prognosis of definitive chemoradiotherapy and clinical features of postoperative lymph node (LN) recurrence after curative resection of thoracic esophageal squamous cell cancer (ESCC).</p><p><strong>Patients and methods: </strong>A total of 586 patients who underwent radical resection of ESCC at the Hiroshima University Hospital from January 2000 to December 2019 were reviewed retrospectively. This study analyzed the clinical characteristics of 54 patients who developed recurrence in a solitary LN by comparing them to 182 patients who experienced total recurrence. Additionally, we analyzed the prognostic factors of 50 patients who received chemo-radiotherapy (CRT).</p><p><strong>Results: </strong>The results revealed a tendency for a higher incidence of solitary LN recurrence in cases of early esophageal cancer and upper thoracic esophageal cancer among all recurrence cases. The 3-, 5-, and 7-year overall survival (OS) rates were 40.5%, 37.8% and 34.6%, respectively, with a median survival time of 27.9 months. Univariate analysis of OS factors, such as age, depth of the primary tumor at the initial surgery, time to LN recurrence after surgery, site of LN recurrence, and the number of the regional LNs with recurrence showed no significant impact on OS.</p><p><strong>Conclusion: </strong>Approximately 35% of patients with ESCC who experienced LN recurrence after curative resection achieved long-term survival through CRT. Despite the absence of identifiable prognostic factors, CRT proves to be a valuable initial treatment option for LN recurrence.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140868375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dose-escalated Salvage Whole-pelvic Radiotherapy for Biochemical Recurrence After Radical Prostatectomy for High-risk Prostate Cancer. 针对高危前列腺癌根治性前列腺切除术后生化复发的剂量递增救治性全盆腔放疗。
Pub Date : 2024-05-03 eCollection Date: 2024-05-01 DOI: 10.21873/cdp.10326
Shuhei Miyazaki, Yutaro Tasaki, Mika Nakatake, Koichi Honda, Daisuke Nakamura, Akiko Egawa, Nozomi Oki, Kensuke Mitsunari, Yuichiro Nakamura, Ryoichi Imamura, Ryo Toya

Background/aim: To investigate the institutional experience of dose-escalated salvage whole-pelvic radiotherapy (WPRT) with the simultaneous integrated boost (SIB) technique in patients with biochemical recurrence (BCR) after radical prostatectomy for high-risk prostate cancer.

Patients and methods: This retrospective study included 21 patients with BCR who received radical prostatectomy for high-risk prostate cancer and underwent salvage RT. Clinical target volume (CTV) of the whole pelvis (CTV56) included the prostate bed, common iliac, external iliac, internal iliac, and obturator lymph node regions. The boost CTV (CTV66) included the prostate bed. Planning target volumes (PTV) were generated by adding a margin of 6-8 mm to CTV (PTV56 and PTV66). Doses of 56.1 and 66 Gy in 33 fractions were delivered to PTV56 and PTV66, respectively.

Results: The 5-year biochemical progression-free survival, overall survival, and cause-specific survival rates were 72%, 94%, and 94%, respectively. A grade 3 late genitourinary toxicity event of gross hematuria was observed in one patient (4%). Acute and late toxicities of grade ≥3, other than gross hematuria, were not observed in any patient.

Conclusion: Dose-escalated salvage WPRT using the SIB technique provides appropriate tumor control without increasing the incident of significant toxicities.

背景/目的:研究在高危前列腺癌根治性前列腺切除术后生化复发(BCR)患者中使用剂量递增的全盆腔放射治疗(WPRT)和同步综合增强(SIB)技术的机构经验:这项回顾性研究纳入了21名因高危前列腺癌接受根治性前列腺切除术并接受挽救性RT治疗的BCR患者。整个盆腔的临床靶区(CTV)(CTV56)包括前列腺床、髂总淋巴结、髂外淋巴结、髂内淋巴结和闭孔淋巴结区。增强 CTV(CTV66)包括前列腺床。通过在 CTV(PTV56 和 PTV66)上添加 6-8 毫米的边缘生成规划靶体积(PTV)。PTV56和PTV66的剂量分别为56.1 Gy和66 Gy,分33次给药:5年无生化进展生存率、总生存率和病因特异性生存率分别为72%、94%和94%。一名患者(4%)出现了3级晚期泌尿生殖系统毒性,即毛细血尿。除毛细血尿外,未在其他患者中观察到≥3级的急性和晚期毒性:结论:使用SIB技术的剂量递增抢救性WPRT可提供适当的肿瘤控制,同时不会增加明显的毒性事件。
{"title":"Dose-escalated Salvage Whole-pelvic Radiotherapy for Biochemical Recurrence After Radical Prostatectomy for High-risk Prostate Cancer.","authors":"Shuhei Miyazaki, Yutaro Tasaki, Mika Nakatake, Koichi Honda, Daisuke Nakamura, Akiko Egawa, Nozomi Oki, Kensuke Mitsunari, Yuichiro Nakamura, Ryoichi Imamura, Ryo Toya","doi":"10.21873/cdp.10326","DOIUrl":"https://doi.org/10.21873/cdp.10326","url":null,"abstract":"<p><strong>Background/aim: </strong>To investigate the institutional experience of dose-escalated salvage whole-pelvic radiotherapy (WPRT) with the simultaneous integrated boost (SIB) technique in patients with biochemical recurrence (BCR) after radical prostatectomy for high-risk prostate cancer.</p><p><strong>Patients and methods: </strong>This retrospective study included 21 patients with BCR who received radical prostatectomy for high-risk prostate cancer and underwent salvage RT. Clinical target volume (CTV) of the whole pelvis (CTV56) included the prostate bed, common iliac, external iliac, internal iliac, and obturator lymph node regions. The boost CTV (CTV66) included the prostate bed. Planning target volumes (PTV) were generated by adding a margin of 6-8 mm to CTV (PTV56 and PTV66). Doses of 56.1 and 66 Gy in 33 fractions were delivered to PTV56 and PTV66, respectively.</p><p><strong>Results: </strong>The 5-year biochemical progression-free survival, overall survival, and cause-specific survival rates were 72%, 94%, and 94%, respectively. A grade 3 late genitourinary toxicity event of gross hematuria was observed in one patient (4%). Acute and late toxicities of grade ≥3, other than gross hematuria, were not observed in any patient.</p><p><strong>Conclusion: </strong>Dose-escalated salvage WPRT using the SIB technique provides appropriate tumor control without increasing the incident of significant toxicities.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maxillary Sinus NUT Carcinoma: A Case Report. 上颌窦 NUT 癌:病例报告。
Pub Date : 2024-05-03 eCollection Date: 2024-05-01 DOI: 10.21873/cdp.10334
Sayaka Arai, Ryota Tomioka, Yuri Ueda, Akira Shimizu, Isaku Okamoto, Kiyoaki Tsukahara

Background/aim: Nuclear protein in testis (NUT) carcinoma is extremely rare, occurs in the midline of the body, progresses rapidly and is refractory to treatment; most patients die within a year. Here, we describe a case of maxillary sinus NUT carcinoma presenting with epistaxis and nasal obstruction that was treated as a standard head and neck carcinoma.

Case report: The patient was a 41-year-old male with a left buccal swelling; the diagnosis was made of primary NUT carcinoma of the left maxillary sinus and bone metastasis in the cervical spine. After induction chemotherapy with docetaxel plus cisplatin and 5-fluorouracil, the tumor decreased in size, and the patient was further treated with cisplatin and radiation therapy. One month after that, the tumor remained small, however, lung metastasis was observed. Therefore, nivolumab was administered. Cetuximab and paclitaxel were administered after the lung metastasis worsened, but the patient developed progressive disease and died 11 months after diagnosis.

Conclusion: Effective treatments for NUT carcinoma have not yet been established. However, early testing to establish the diagnosis may provide useful insights to guide clinical decisions to improve patient outcomes.

背景/目的:睾丸核蛋白癌(NUT)极为罕见,发生于身体中线,进展迅速且难治,大多数患者在一年内死亡。在此,我们描述了一例上颌窦 NUT 癌病例,患者出现鼻衄和鼻塞,被当作标准的头颈部癌治疗:患者为 41 岁男性,左侧口腔肿物;诊断为左侧上颌窦原发性 NUT 癌和颈椎骨转移。多西他赛+顺铂和 5-氟尿嘧啶诱导化疗后,肿瘤缩小,患者又接受了顺铂和放射治疗。一个月后,肿瘤仍然很小,但出现了肺转移。因此,患者接受了尼妥珠单抗治疗。肺转移恶化后,患者又接受了西妥昔单抗和紫杉醇治疗,但病情仍在进展,确诊后11个月死亡:结论:NUT 癌的有效治疗方法尚未确立。然而,早期检测确诊可为临床决策提供有益的指导,从而改善患者的预后。
{"title":"Maxillary Sinus NUT Carcinoma: A Case Report.","authors":"Sayaka Arai, Ryota Tomioka, Yuri Ueda, Akira Shimizu, Isaku Okamoto, Kiyoaki Tsukahara","doi":"10.21873/cdp.10334","DOIUrl":"https://doi.org/10.21873/cdp.10334","url":null,"abstract":"<p><strong>Background/aim: </strong>Nuclear protein in testis (NUT) carcinoma is extremely rare, occurs in the midline of the body, progresses rapidly and is refractory to treatment; most patients die within a year. Here, we describe a case of maxillary sinus NUT carcinoma presenting with epistaxis and nasal obstruction that was treated as a standard head and neck carcinoma.</p><p><strong>Case report: </strong>The patient was a 41-year-old male with a left buccal swelling; the diagnosis was made of primary NUT carcinoma of the left maxillary sinus and bone metastasis in the cervical spine. After induction chemotherapy with docetaxel plus cisplatin and 5-fluorouracil, the tumor decreased in size, and the patient was further treated with cisplatin and radiation therapy. One month after that, the tumor remained small, however, lung metastasis was observed. Therefore, nivolumab was administered. Cetuximab and paclitaxel were administered after the lung metastasis worsened, but the patient developed progressive disease and died 11 months after diagnosis.</p><p><strong>Conclusion: </strong>Effective treatments for NUT carcinoma have not yet been established. However, early testing to establish the diagnosis may provide useful insights to guide clinical decisions to improve patient outcomes.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062161/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140857217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First Case Report of Bilateral Parotid Lymphoepithelial Carcinoma. 首例双侧腮腺淋巴上皮癌病例报告
Pub Date : 2024-05-03 eCollection Date: 2024-05-01 DOI: 10.21873/cdp.10336
Willer Everton Feitosa Meneses, Pedro Henrique Cunha Lima DO Rego, Valdenor Neves Feitosa Junior, Herbert Tavares Palmeira, Douglas Henning Pinheiro Aragao, Andre Costa Teixeira, Pedro Lucena DE Aquino, Pedro Miguel Azevedo Pinheiro, Joao Pedro Targino Silva, Francisco Julimar Correia DE Menezes, Matheus Januario DA Silva, Gabriel Gurgel Silva Fernandes

Background/aim: The parotid is the largest salivary gland and is located anteriorly to the sternocleidomastoid muscle and laterally to the ramus of the mandible. Neoplasms in this gland are relatively rare, with 80% being benign and 20% malignant, primarily represented by mucoepidermoid carcinoma. In the head and neck region, lymphoepithelial carcinoma (LEC) accounts for 0.4% of malignant salivary gland tumors.

Case report: A 35-year-old man with no previous comorbidities was admitted to a Head and Neck Surgery Specialty Service for a painless right cervical mass of uncertain growth. Extensive diagnostic investigation revealed involvement of the contralateral parotid, associated with systemic lymph node enlargement. Thus, adjuvant radiotherapy was decided by the treating team.

Conclusion: This case confirms the heterogeneous features and distinctive behavior that the disease can present, as seen with bilateral parotid LEC.

背景/目的:腮腺是最大的唾液腺,位于胸锁乳突肌的前方和下颌骨横突的侧面。该腺体的肿瘤相对罕见,80%为良性,20%为恶性,主要是粘液表皮样癌。在头颈部地区,淋巴上皮癌(LEC)占恶性唾液腺肿瘤的 0.4%:病例报告:一名 35 岁的男性因右侧颈部生长不确定的无痛性肿块入住头颈外科专科。广泛的诊断检查发现对侧腮腺受累,并伴有全身淋巴结肿大。因此,治疗小组决定进行辅助放疗:本病例证实了双侧腮腺 LEC 可表现出的异质性特征和独特行为。
{"title":"First Case Report of Bilateral Parotid Lymphoepithelial Carcinoma.","authors":"Willer Everton Feitosa Meneses, Pedro Henrique Cunha Lima DO Rego, Valdenor Neves Feitosa Junior, Herbert Tavares Palmeira, Douglas Henning Pinheiro Aragao, Andre Costa Teixeira, Pedro Lucena DE Aquino, Pedro Miguel Azevedo Pinheiro, Joao Pedro Targino Silva, Francisco Julimar Correia DE Menezes, Matheus Januario DA Silva, Gabriel Gurgel Silva Fernandes","doi":"10.21873/cdp.10336","DOIUrl":"https://doi.org/10.21873/cdp.10336","url":null,"abstract":"<p><strong>Background/aim: </strong>The parotid is the largest salivary gland and is located anteriorly to the sternocleidomastoid muscle and laterally to the ramus of the mandible. Neoplasms in this gland are relatively rare, with 80% being benign and 20% malignant, primarily represented by mucoepidermoid carcinoma. In the head and neck region, lymphoepithelial carcinoma (LEC) accounts for 0.4% of malignant salivary gland tumors.</p><p><strong>Case report: </strong>A 35-year-old man with no previous comorbidities was admitted to a Head and Neck Surgery Specialty Service for a painless right cervical mass of uncertain growth. Extensive diagnostic investigation revealed involvement of the contralateral parotid, associated with systemic lymph node enlargement. Thus, adjuvant radiotherapy was decided by the treating team.</p><p><strong>Conclusion: </strong>This case confirms the heterogeneous features and distinctive behavior that the disease can present, as seen with bilateral parotid LEC.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062164/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140873638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Rare Inflammatory Myofibroblastic Tumor of the Spleen: A Case Report. 罕见的脾脏炎性肌纤维母细胞瘤:病例报告。
Pub Date : 2024-05-03 eCollection Date: 2024-05-01 DOI: 10.21873/cdp.10335
Dimitris Fagkrezos, Marina Kakavelou, Evgenia Charitaki, Spiros Delis, Kleo Papaparaskeva, Charikleia Triantopoulou, Petros Maniatis, Dimosthenis Chrysikos, Theodore Troupis

Background/aim: Inflammatory myofibroblastic tumors (IMTs) are rare, solid, potentially malignant lesions of uncertain etiology. Histologically, IMTs exhibit a combination of lymphocytes and inflammatory cells within a fibroblastic myxoid layer. The diagnosis of IMTs poses a challenge for various medical specialties, including surgeons, pathologists, and oncologists, due to their non-specific clinical presentation. Furthermore, radiologists face difficulties in interpreting computed tomography (CT) or magnetic resonance imaging (MRI) results, which often yield polymorphic and inconclusive findings. Ultimately, histopathologists play a crucial role in reaching a definitive diagnosis based on the tumor's histological characteristics. They are detected in every system of the human body, most commonly in the lungs. Here, we report an uncommon occurrence of IMT in the spleen of a patient with nonspecific abdominal pain.

Case report: A 56-year-old Caucasian female presented to Konstantopouleio General Hospital of Nea Ionia, Athens, Greece, with abdominal pain and discomfort. The patient had no significant medical history and normal laboratory tests. An abdominal CT revealed a large mass in the spleen. A splenectomy was performed. Histopathological analysis of the tumor revealed IMTS.

Conclusion: Splenic IMT is a rare benign tumor with moderate malignant potential. It lacks a distinct clinical presentation and is typically identified either incidentally or during the examination of abdominal pain.

背景/目的:炎性肌纤维母细胞瘤(IMTs)是一种罕见的实体瘤,可能是病因不明的恶性病变。从组织学角度看,炎性肌纤维母细胞瘤的纤维肌层内有淋巴细胞和炎性细胞。由于 IMTs 的临床表现无特异性,因此对包括外科医生、病理学家和肿瘤学家在内的各医学专科医师来说,IMTs 的诊断是一项挑战。此外,放射科医生在解释计算机断层扫描(CT)或磁共振成像(MRI)结果时也会遇到困难,因为这些结果往往会产生多形性和不确定的结果。最终,组织病理学家在根据肿瘤的组织学特征做出明确诊断方面发挥着至关重要的作用。在人体的各个系统中都能发现这种肿瘤,最常见的是在肺部。在此,我们报告了一名非特异性腹痛患者的脾脏中发生的一种罕见的 IMT:一名 56 岁的高加索女性因腹部疼痛和不适来到希腊雅典新爱奥尼亚 Konstantopouleio 综合医院就诊。患者无明显病史,实验室检查正常。腹部 CT 显示脾脏内有一个巨大肿块。患者接受了脾脏切除术。肿瘤的组织病理分析显示为IMTS:结论:脾IMT是一种罕见的良性肿瘤,具有中度恶性潜能。结论:脾IMT是一种罕见的良性肿瘤,具有中度恶性潜能。它没有明显的临床表现,通常是偶然发现或在腹痛检查中发现。
{"title":"A Rare Inflammatory Myofibroblastic Tumor of the Spleen: A Case Report.","authors":"Dimitris Fagkrezos, Marina Kakavelou, Evgenia Charitaki, Spiros Delis, Kleo Papaparaskeva, Charikleia Triantopoulou, Petros Maniatis, Dimosthenis Chrysikos, Theodore Troupis","doi":"10.21873/cdp.10335","DOIUrl":"https://doi.org/10.21873/cdp.10335","url":null,"abstract":"<p><strong>Background/aim: </strong>Inflammatory myofibroblastic tumors (IMTs) are rare, solid, potentially malignant lesions of uncertain etiology. Histologically, IMTs exhibit a combination of lymphocytes and inflammatory cells within a fibroblastic myxoid layer. The diagnosis of IMTs poses a challenge for various medical specialties, including surgeons, pathologists, and oncologists, due to their non-specific clinical presentation. Furthermore, radiologists face difficulties in interpreting computed tomography (CT) or magnetic resonance imaging (MRI) results, which often yield polymorphic and inconclusive findings. Ultimately, histopathologists play a crucial role in reaching a definitive diagnosis based on the tumor's histological characteristics. They are detected in every system of the human body, most commonly in the lungs. Here, we report an uncommon occurrence of IMT in the spleen of a patient with nonspecific abdominal pain.</p><p><strong>Case report: </strong>A 56-year-old Caucasian female presented to Konstantopouleio General Hospital of Nea Ionia, Athens, Greece, with abdominal pain and discomfort. The patient had no significant medical history and normal laboratory tests. An abdominal CT revealed a large mass in the spleen. A splenectomy was performed. Histopathological analysis of the tumor revealed IMTS.</p><p><strong>Conclusion: </strong>Splenic IMT is a rare benign tumor with moderate malignant potential. It lacks a distinct clinical presentation and is typically identified either incidentally or during the examination of abdominal pain.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140873235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short-course Radiotherapy for Airway Stenting in Malignant Airway Obstruction: A Case Report and Literature Review. 恶性气道阻塞时气道支架植入术的短程放疗:病例报告与文献综述
Pub Date : 2024-05-03 eCollection Date: 2024-05-01 DOI: 10.21873/cdp.10332
Giuseppe Facondo, Chiara Reverberi, Tino Ceschia, Giuseppe Parisi, Gianluca Vullo, Eugenia Moretti, Marco Trovò

Background: Malignant airway obstruction (MAO) secondary to tumor growth occurs in nearly a third of patients with lung cancer and portends a very poor prognosis if untreated. Treatment options include bronchoscopic intervention with tumor debulking, stent placement, endobronchial brachytherapy, or palliative radiotherapy.

Case report: This is a report of a 74-year-old woman with a medical history of metastatic lung adenocarcinoma, hospitalized for dyspnea, hemoptysis, and chest pain with a radiographic finding of MAO on chest X-ray and computed tomography. Patient underwent radiation with a total dose of 13 Gy in two once-weekly fractions of 6.5 Gy per fraction. Three days after the end of radiation treatment, chest X-ray showed a completely right lung re-expansion without atelectasis. Two weeks after radiotherapy treatment, the patient was discharged from hospital without pulmonary symptoms.

Conclusion: A different fractionation with a lower equivalent dose in 2 Gy fraction compared to literature data showed efficacy in resolving MAO with excellent local control in the first three months of follow-up.

背景:近三分之一的肺癌患者会出现继发于肿瘤生长的恶性气道阻塞(MAO),如不及时治疗,预后极差。治疗方案包括支气管镜介入肿瘤剥离、支架置入、支气管内近距离放疗或姑息性放疗:这是一份关于一名 74 岁女性的报告,她有转移性肺腺癌病史,因呼吸困难、咯血和胸痛住院,胸部 X 光和计算机断层扫描发现 MAO。患者接受了总剂量为 13 Gy 的放射治疗,分两次进行,每周一次,每次 6.5 Gy。放疗结束三天后,胸部 X 光片显示右肺完全再扩张,无肺不张。放疗两周后,患者出院,未出现肺部症状:结论:与文献数据相比,2 Gy 分段等效剂量较低的不同分次放疗在治疗 MAO 方面效果显著,在最初三个月的随访中,局部控制良好。
{"title":"Short-course Radiotherapy for Airway Stenting in Malignant Airway Obstruction: A Case Report and Literature Review.","authors":"Giuseppe Facondo, Chiara Reverberi, Tino Ceschia, Giuseppe Parisi, Gianluca Vullo, Eugenia Moretti, Marco Trovò","doi":"10.21873/cdp.10332","DOIUrl":"https://doi.org/10.21873/cdp.10332","url":null,"abstract":"<p><strong>Background: </strong>Malignant airway obstruction (MAO) secondary to tumor growth occurs in nearly a third of patients with lung cancer and portends a very poor prognosis if untreated. Treatment options include bronchoscopic intervention with tumor debulking, stent placement, endobronchial brachytherapy, or palliative radiotherapy.</p><p><strong>Case report: </strong>This is a report of a 74-year-old woman with a medical history of metastatic lung adenocarcinoma, hospitalized for dyspnea, hemoptysis, and chest pain with a radiographic finding of MAO on chest X-ray and computed tomography. Patient underwent radiation with a total dose of 13 Gy in two once-weekly fractions of 6.5 Gy per fraction. Three days after the end of radiation treatment, chest X-ray showed a completely right lung re-expansion without atelectasis. Two weeks after radiotherapy treatment, the patient was discharged from hospital without pulmonary symptoms.</p><p><strong>Conclusion: </strong>A different fractionation with a lower equivalent dose in 2 Gy fraction compared to literature data showed efficacy in resolving MAO with excellent local control in the first three months of follow-up.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140874034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer diagnosis & prognosis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1